RFG Advisory LLC Sells 4,089 Shares of IDEXX Laboratories, Inc. $IDXX

RFG Advisory LLC lowered its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 60.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,687 shares of the company’s stock after selling 4,089 shares during the period. RFG Advisory LLC’s holdings in IDEXX Laboratories were worth $1,716,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. WealthCollab LLC acquired a new stake in IDEXX Laboratories in the 2nd quarter worth approximately $30,000. J.Safra Asset Management Corp bought a new stake in shares of IDEXX Laboratories during the 3rd quarter worth $31,000. Armstrong Advisory Group Inc. grew its stake in IDEXX Laboratories by 55.9% in the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock valued at $34,000 after buying an additional 19 shares during the last quarter. Salomon & Ludwin LLC acquired a new stake in shares of IDEXX Laboratories in the third quarter valued at about $35,000. Finally, Greykasell Wealth Strategies Inc. acquired a new stake in IDEXX Laboratories in the 3rd quarter valued at approximately $35,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Leerink Partners set a $785.00 price objective on shares of IDEXX Laboratories in a report on Monday, November 3rd. Stifel Nicolaus set a $775.00 price objective on IDEXX Laboratories in a research note on Monday, November 3rd. Weiss Ratings cut IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. UBS Group decreased their price target on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 3rd. Finally, Barclays lowered their price target on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Seven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $783.33.

IDEXX Laboratories Trading Up 1.1%

IDXX opened at $646.53 on Wednesday. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $51.63 billion, a PE ratio of 49.47, a PEG ratio of 3.89 and a beta of 1.67. The firm has a 50-day moving average price of $690.23 and a two-hundred day moving average price of $667.06. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, February 2nd. The company reported $3.08 EPS for the quarter, beating analysts’ consensus estimates of $2.93 by $0.15. The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The business’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period last year, the company earned $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, equities analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.